You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Brigatinib

Showing 26 - 35 of 35
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK+ Advanced NSCLC Trial in Worldwide (Brigatinib, Alectinib)

Recruiting
  • ALK+ Advanced NSCLC
  • Whittier, California
  • +113 more
Apr 1, 2022

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors

Withdrawn
  • Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
  • +2 more
  • Brigatinib
  • Brigatinib AAF
  • (no location specified)
Mar 2, 2020

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer Trial in Italy (Erlotinib, Trastuzumab, Trastuzumab

Recruiting
  • Breast Cancer
  • +3 more
  • Ancona, Italy
  • +40 more
Jan 25, 2023

NSCLC, Lung Cancer, Advanced Malignancies Trial in Worldwide (Brigatinib, Crizotinib)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • +3 more
  • Sedona, Arizona
  • +90 more
Jul 27, 2021

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Angers, France
  • +31 more
Apr 12, 2022

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021

NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)

Recruiting
  • Non-small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • RNAseq
  • Saint-Denis, La Réunion, France
  • +44 more
Nov 4, 2021

NSCLC, Lung Cancer, Advanced Malignancies Trial in La Jolla, Orange, Detroit (Brigatinib)

No longer available
  • Non-small Cell Lung Cancer
  • +3 more
  • Brigatinib
  • La Jolla, California
  • +2 more
Feb 5, 2018

Plasma NGS for Assessment, Characterization, Evaluation of ALK

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Plasma Next Generation Sequencing (NGS)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 26, 2023